Highlights and Quick Summary
- Quick Ratio for the quarter ending June 29, 2021 was 5.29 (a -9.15% decrease compared to previous quarter)
- Year-over-year quarterly Quick Ratio decreased by -35.3%
- Annual Quick Ratio for 2020 was 5.18 (a -92.04% decrease from previous year)
- Annual Quick Ratio for 2019 was 65.04 (a 16090.86% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Quick Ratio of Phathom Pharmaceuticals, Inc.Most recent Quick Ratioof PHAT including historical data for past 10 years.
Interactive Chart of Quick Ratio of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Quick Ratio for the past 10 Years (both Annual and Quarterly)
Business Profile of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.